Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...
It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...
WBRE Wilkes-Barre on MSN4h
Commonwealth University to vote on president’s futureCommonwealth University’s faculty and coaches are set to take a no-confidence vote on the University’s president on February ...
Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.
WETM Elmira on MSN4h
Commonwealth University faculty, coaches, to take no-confidence vote on university presidentFaculty and coaches from three campuses of Commonwealth University will vote anonymously in February to give their voice in ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...
Bariatric surgery significantly reduced long-term risk for decompensation and adverse outcomes in patients with obesity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback